Synlogic Shares Outstanding 2013-2021 | SYBX

Synlogic shares outstanding from 2013 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Synlogic Annual Shares Outstanding
(Millions of Shares)
2020 36
2019 30
2018 24
2017 7
2016 2
2015 1
2014 0
2013 0
2012 0
Synlogic Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 52
2021-03-31 42
2020-12-31 36
2020-09-30 36
2020-06-30 35
2020-03-31 34
2019-12-31 30
2019-09-30 34
2019-06-30 27
2019-03-31 25
2018-12-31 24
2018-09-30 25
2018-06-30 25
2018-03-31 20
2017-12-31 7
2017-09-30 7
2017-06-30 2
2017-03-31 2
2016-12-31 2
2016-09-30 2
2016-06-30 3
2016-03-31 3
2015-12-31 1
2015-09-30 0
2015-06-30 0
2015-03-31 0
2014-12-31
2014-09-30 12
2014-06-30
2013-12-31
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.140B $0.001B
Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76